Heparin Sodium Wockhardt Uk

Heparin Sodium Wockhardt UK is an injectable anticoagulant containing the active ingredient heparin sodium. It is supplied as a sterile intravenous solution and is marketed in the European Union. The product is prescription‑only and belongs to the antithrombotic drug class, acting through activation of antithrombin III to inhibit clotting factors IIa and Xa. It is used under medical supervision for thromboembolic conditions and related vascular disorders.

Heparin Sodium Wockhardt UK is indicated for several antithrombotic indications in hospital settings.

- Prevention and treatment of venous thromboembolism, including deep vein thrombosis and pulmonary embolism. - Prophylaxis of deep vein thrombosis in patients undergoing surgery or immobilization. - Management of acute coronary syndromes, such as unstable angina and non‑ST‑segment elevation myocardial infarction. - Use during cardiac bypass or other cardiovascular procedures requiring anticoagulation. - Treatment of clotting disorders in patients at risk for heparin‑induced thrombocytopenia, under specialist guidance.

Adverse reactions to Heparin Sodium Wockhardt UK vary in frequency and severity.

Common: - Minor bleeding at the injection site. - Small bruising or hematoma formation. - Mild nausea or vomiting. - Transient elevation of liver enzymes. - Mild thrombocytopenia without clinical bleeding. - Elevated activated partial thromboplastin time (aPTT).

Serious: - Major hemorrhage, including intracranial or gastrointestinal bleeding. - Heparin‑induced thrombocytopenia (HIT) with risk of thrombosis. - Spinal or epidural hematoma when used near the central nervous system. - Allergic reactions such as urticaria, angioedema, or anaphylaxis. - Severe drop in blood pressure (hypotension) due to systemic anticoagulation. - Organ failure secondary to massive bleeding.

When prescribing Heparin Sodium Wockhardt UK, clinicians should consider several safety precautions to minimize risk.

- Assess baseline coagulation status and platelet count before initiation. - Adjust dose in patients with renal or hepatic impairment. - Monitor activated partial thromboplastin time (aPTT) regularly during therapy. - Avoid use in patients with active major bleeding or recent intracranial hemorrhage. - Use caution in pregnancy; benefits must outweigh potential risks. - Discontinue promptly if signs of heparin‑induced thrombocytopenia appear. - Review concomitant use of other anticoagulants or antiplatelet agents.

Heparin Sodium Wockhardt UK can interact with other medications that affect hemostasis or platelet function.

Avoid: - Concurrent use of other parenteral anticoagulants (e.g., direct thrombin inhibitors) unless specifically directed. - Combination with thrombolytic agents such as alteplase or streptokinase. - Use with high‑dose aspirin or non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase bleeding risk.

Use with caution: - Dual antiplatelet therapy (e.g., clopidogrel plus aspirin). - Certain antibiotics (e.g., cefazolin) that may potentiate anticoagulant effect. - Glycoprotein IIb/IIIa inhibitors. - Vitamin K antagonists (warfarin) during transition phases. - Antifibrinolytics (e.g., tranexamic acid) when bleeding control is needed.